Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project

Research output: Contribution to journalArticle

Standard

Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project. / Rimpler, A.; Barth, I.; Ferrari, Paolo; Baechler, Sebastien; Carnicer, Adela; Donadille, Laurent; Fulop, M.; Ginjaume, Mercè; Mariotti, M.; Sans-Mercé, Marta; Gualdrini, G.; Krim, Sabah; Ortega, Xavier; Ruiz, Natasha; Vanhavere, Filip.

In: Radiation Measurements, Vol. 46, No. 11, 11.2011, p. 1283-1286.

Research output: Contribution to journalArticle

Harvard

Rimpler, A, Barth, I, Ferrari, P, Baechler, S, Carnicer, A, Donadille, L, Fulop, M, Ginjaume, M, Mariotti, M, Sans-Mercé, M, Gualdrini, G, Krim, S, Ortega, X, Ruiz, N & Vanhavere, F 2011, 'Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project', Radiation Measurements, vol. 46, no. 11, pp. 1283-1286. https://doi.org/10.1016/j.radmeas.2011.05.068

APA

Rimpler, A., Barth, I., Ferrari, P., Baechler, S., Carnicer, A., Donadille, L., ... Vanhavere, F. (2011). Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project. Radiation Measurements, 46(11), 1283-1286. https://doi.org/10.1016/j.radmeas.2011.05.068

Vancouver

Rimpler A, Barth I, Ferrari P, Baechler S, Carnicer A, Donadille L et al. Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project. Radiation Measurements. 2011 Nov;46(11):1283-1286. https://doi.org/10.1016/j.radmeas.2011.05.068

Author

Rimpler, A. ; Barth, I. ; Ferrari, Paolo ; Baechler, Sebastien ; Carnicer, Adela ; Donadille, Laurent ; Fulop, M. ; Ginjaume, Mercè ; Mariotti, M. ; Sans-Mercé, Marta ; Gualdrini, G. ; Krim, Sabah ; Ortega, Xavier ; Ruiz, Natasha ; Vanhavere, Filip. / Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project. In: Radiation Measurements. 2011 ; Vol. 46, No. 11. pp. 1283-1286.

Bibtex - Download

@article{c4fcdb0057764a44a370373181a22b3e,
title = "Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project",
abstract = "90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (EANM, 2007), peptide receptor radiotherapies (PRRT), (Otte et al., 1998), and selective internal radiotherapies (SIRT), (Salem and Thurston, 2006). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin{\circledR} and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff.",
keywords = "Nuclear medicine, Radiation exposure, Skin dose, Individual monitoring",
author = "A. Rimpler and I. Barth and Paolo Ferrari and Sebastien Baechler and Adela Carnicer and Laurent Donadille and M. Fulop and Merc{\`e} Ginjaume and M. Mariotti and Marta Sans-Merc{\'e} and G. Gualdrini and Sabah Krim and Xavier Ortega and Natasha Ruiz and Filip Vanhavere",
note = "Score=10",
year = "2011",
month = "11",
doi = "10.1016/j.radmeas.2011.05.068",
language = "English",
volume = "46",
pages = "1283--1286",
journal = "Radiation Measurements",
issn = "1350-4487",
publisher = "Elsevier",
number = "11",

}

RIS - Download

TY - JOUR

T1 - Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project

AU - Rimpler, A.

AU - Barth, I.

AU - Ferrari, Paolo

AU - Baechler, Sebastien

AU - Carnicer, Adela

AU - Donadille, Laurent

AU - Fulop, M.

AU - Ginjaume, Mercè

AU - Mariotti, M.

AU - Sans-Mercé, Marta

AU - Gualdrini, G.

AU - Krim, Sabah

AU - Ortega, Xavier

AU - Ruiz, Natasha

AU - Vanhavere, Filip

N1 - Score=10

PY - 2011/11

Y1 - 2011/11

N2 - 90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (EANM, 2007), peptide receptor radiotherapies (PRRT), (Otte et al., 1998), and selective internal radiotherapies (SIRT), (Salem and Thurston, 2006). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin® and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff.

AB - 90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (EANM, 2007), peptide receptor radiotherapies (PRRT), (Otte et al., 1998), and selective internal radiotherapies (SIRT), (Salem and Thurston, 2006). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin® and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff.

KW - Nuclear medicine

KW - Radiation exposure

KW - Skin dose

KW - Individual monitoring

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/overview/ezp_124593

U2 - 10.1016/j.radmeas.2011.05.068

DO - 10.1016/j.radmeas.2011.05.068

M3 - Article

VL - 46

SP - 1283

EP - 1286

JO - Radiation Measurements

JF - Radiation Measurements

SN - 1350-4487

IS - 11

ER -

ID: 6869496